Corrona Revenue and Competitors
Estimated Revenue & Valuation
- Corrona's estimated annual revenue is currently $64.4M per year.
- Corrona's estimated revenue per employee is $297,000
- Corrona has 217 Employees.
- Corrona grew their employee count by 14% last year.
Corrona Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Corrona?
Corrona is a nationwide provider of disease registries. Corrona was founded in 2001 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides longitudinal clinical data, patient reported measures, and research results to biopharmaceutical companies. Corrona data analysis provides a rich framework in which to explore topics such as comparative effectiveness, post market safety reporting, and commercial applications. Data are collected at the time of a routine clinical encounter from both physicians and patients. The data are combined for novel insights. Corrona has published over 100 peer-reviewed manuscripts and 300 abstracts. These publications have added significant value into better understanding the safety and efficacy of drugs for treating patients with autoimmune diseases. Corrona's data are universally respected as a source of reliable data in our disease. In addition to its flagship registry in rheumatoid arthritis (RA), Corrona has registries in the USA in psoriasis, spondylosing arthropathies (SpA/PsA), irritable bowel disease (IBD), and is most recently launched a registry in multiple sclerosis. Corrona has also launched an RA registry in Japan.keywords:Biotechnology,Healthcare,Healthcare Providers,Pharmaceuticals
Number of Employees
Employee Growth %
“Corrona's mission is to advance medical research and improve patient care by providing unique data on treatment efficacy and outcomes of ...
WALTHAM, Mass., May 20, 2019 /PRNewswire/ -- Corrona, LLC is pleased to announce a key milestone for the Corrona® Multiple Sclerosis ...
Roche's Genentech becomes the first pharmaceutical company included in the Corrona Multiple Sclerosis Registry, to support clinical research.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|